TriSalus Life Sciences, Inc. 8K

TriSalus Life Sciences, Inc. announced first quarter 2026 results, strengthened its balance sheet with a $46 million equity raise, updated 2026 revenue guidance to $54–$57 million amid commercial expansion and delayed FDA clearance of TriNav Advance, and reported significant clinical, commercial, and leadership developments for its PEDD platform and pipeline.

On May 12, 2026, TriSalus Life Sciences, Inc. reported its financial results for the quarter ended March 31, 2026, highlighting $8.9 million in TriNav system revenue (a slight year-over-year decline), improved gross margins, and a swing to GAAP net income driven primarily by non-cash gains on derivative liabilities, while also announcing completion of a $46 million equity offering that increased its cash balance to $56.6 million to fund commercial expansion and pipeline development. The company detailed commercial and clinical progress for its Pressure-Enabled Drug Delivery (PEDD) platform, including publication of a large real-world outcomes study and new clinical and preclinical data across multiple oncology and embolization applications, revised its full-year 2026 revenue guidance to $54–$57 million to reflect commercial expansion effects and delayed FDA clearance for its next-generation TriNav Advance device, and disclosed governance and management updates with the appointment of Michael P. Stansky to the Board and Richard Marshall, M.D., as Chief Medical Officer effective June 29, 2026. Management emphasized that the expanded commercial organization and strengthened balance sheet position the company for long-term growth while it advances its PEDD-based device portfolio and its investigational immunotherapeutic nelitolimod.

Filing Facts

CIK

1826667

Ticker

-

Form

8K

Source Type

sec

Accession

0001628280-26-034082

Alert Tier

6